Monday 8 June 2026

One To Watch

Xilio Therapeutics

A clinical-stage biotechnology company developing tumor-activated immuno-oncology therapies.

Company Overview

Want to Update your Company's Profile?


Latest Xilio Therapeutics News

Xilio’s Stacey Davis recruited by Enara
1 May 2025
AbbVie expands oncology R&D with Xilio deal
12 February 2025
Xilio shares tumble after mixed vilastobart data
23 January 2025
Gilead punts $43.5 million on Xilio asset
28 March 2024
More Xilio Therapeutics news >


Today's issue

AdvanCell strengthens executive leadership
Pharmaceutical
AdvanCell strengthens executive leadership
8 June 2026
Biotechnology
Sanofi expands AI ambitions through new Owkin collaboration
8 June 2026
Pharmaceutical
MannKind highlights wider role for Afrezza at ADA 2026
8 June 2026
Pharmaceutical
A missing perspective: the burden of skin disease in women
8 June 2026
Biotechnology
Engitix inks collaboration with GSK for liver fibrosis drugs
8 June 2026
Pharmaceutical
Boehringer obesity drug shows fat loss gains but tolerability clouds ADA readout
8 June 2026
Pharmaceutical
Diabetes data bolster CagriSema ahead of obesity decision
8 June 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze